Hematologic diseases (hematonosis), disorders of the blood and blood-forming organs, afflict millions of Americans. In addition to hematological malignancies, such as leukemia and lymphomas, children and adolescents can suffer blood disorder, that are not classified as cancer, but may lead to severe diseases and therefore require treatment. These blood disorders include severe aplastic anemia (SAA), thalassemia, immune (idiopathic) thrombocytopenic purpura, congenital neutropenia, hemophilia, sickle-cell disease, iron deficiency anemia and various other diseases. In the past, due to the lack of effective treatments, many diseases have been called "incurable diseases". In recent years, with in-depth development of medical research, the treatment of blood diseases has been significantly improved. Modern medicine uses hormones, chemotherapy and other methods for the treatment of blood diseases, but the side effects are large, and the patient has a low cure rate and is prone to recurrence. Bone marrow transplantation for the treatment of leukemia was introduced then the cure rate of leukemia was improved. However, the bone marrow resources were very scarce, and a large part of the donated bone marrow was inconsistent with the patient's HLA, even if the transplant was successful, and the recurrence rate was as high as 70% within 5 years. Therefore, it is necessary to develop new therapies and drugs for the treatment of hematologic diseases.
Hematonosis Compound Library from TargetMol provides you with compounds related to hematologic diseases that can be used for high throughput and high content screening.
|100 μL * 10 mM (in DMSO)||1890.00|
|250 μL * 10 mM (in DMSO)||3276.00|